Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary

Tamara Gracia Cazaña, MD, PhD; Josep Riera Monroig, MD; Rosa Izu, MD, PhD; Ignacio Yanguas, MD, PhD; Marta Lorda Espés, MD, PhD; María Pilar Sánchez Salas, MD; Miguel Fernando García Gil, MD; Alba Navarro Bielsa, MD; Beatriz Aldea Manrique, MD; Manuel Almenara Blasco, MD; Francisco Javier García-Latasa de Araníbar, MD, PhD; Victoria Fuentelsaz, MD, PhD; Ana Morales Callaghan, MD, PhD; Mariano Ara-Martín, MD, PhD

JAAD International (Sep 2024)

Real-world outcomes in patients with malignancy and moderate-to-severe psoriasis treated with guselkumabCapsule Summary

Tamara Gracia Cazaña, MD, PhD,
Josep Riera Monroig, MD,
Rosa Izu, MD, PhD,
Ignacio Yanguas, MD, PhD,
Marta Lorda Espés, MD, PhD,
María Pilar Sánchez Salas, MD,
Miguel Fernando García Gil, MD,
Alba Navarro Bielsa, MD,
Beatriz Aldea Manrique, MD,
Manuel Almenara Blasco, MD,
Francisco Javier García-Latasa de Araníbar, MD, PhD,
Victoria Fuentelsaz, MD, PhD,
Ana Morales Callaghan, MD, PhD,
Mariano Ara-Martín, MD, PhD

Affiliations

Tamara Gracia Cazaña, MD, PhD: Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain; Correspondence to: Tamara Gracia Cazaña, MD, PhD, Department of Dermatology, Miguel Servet University Hospital, IIS Aragón, University of Zaragoza, Paseo Isabel la Católica 1-3, Zaragoza 50009, Spain.
Josep Riera Monroig, MD: Department of Dermatology, Hospital Clinic de Barcelona, Universitat de Barcelona, Barcelona, Spain
Rosa Izu, MD, PhD: Department of Dermatology, Basurto University Hospital, Bilbao, Spain
Ignacio Yanguas, MD, PhD: Department of Dermatology, Complejo Hospitalario de Navarra, Pamplona, Spain
Marta Lorda Espés, MD, PhD: Department of Dermatology, Lozano Blesa University Hospital Zaragoza, Zaragoza, Spain
María Pilar Sánchez Salas, MD: Dermatology Unit, Hospital de Barbastro, Huesca, Spain
Miguel Fernando García Gil, MD: Dermatology Unit, Hospital Obispo Polanco, Teruel, Spain
Alba Navarro Bielsa, MD: Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain
Beatriz Aldea Manrique, MD: Dermatology Unit, San Pedro Hospital, Logroño, Spain
Manuel Almenara Blasco, MD: Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain
Francisco Javier García-Latasa de Araníbar, MD, PhD: Department of Dermatology, Hospital Royo Villanova, Zaragoza, Spain
Victoria Fuentelsaz, MD, PhD: Department of Dermatology, Hospital Royo Villanova, Zaragoza, Spain
Ana Morales Callaghan, MD, PhD: Department of Dermatology, Miguel Servet University Hospital, Instituto de Investigación Sanitaria de Aragón, University of Zaragoza, Zaragoza, Spain
Mariano Ara-Martín, MD, PhD: Department of Dermatology, Lozano Blesa University Hospital Zaragoza, Zaragoza, Spain

Journal volume & issue: Vol. 16
pp. 66 – 71

Abstract

Read online

Background: The treatment of psoriasis in patients with a personal history of cancer is a matter of debate and limited evidence is available to guide clinicians. Objectives: To report a multicenter real-life experience of a group of patients with psoriasis undergoing treatment with guselkumab and a history of cancer. Methods: We conducted a multicenter retrospective Spanish study enrolling patients with moderate-to-severe plaque psoriasis and neoplasia being treated with guselkumab for their psoriasis. Results: Twenty patients with moderate-to-severe psoriasis and at least 12 weeks of ongoing treatment were included. For the analysis, a 52 week follow-up period was evaluated in terms of efficacy and safety. Most of the malignancies in these patients were solid tumors. The percentage of patients achieving psoriasis area and severity index ≤3 at week 12 and week 52 was 80% and 87.5%, respectively, whereas 68.8% of patients achieved psoriasis area and severity index ≤1. A 52-week survival rate of 100% in the study population was observed (n = 20), including those patients with concomitant active cancers (n = 14). No adverse effects or dropouts related to guselkumab safety profile were detected. Limitations: Modest sample size and the retrospective nature of the study. Conclusion: Guselkumab not only demonstrates high effectiveness in treating psoriasis but also exhibits a favorable safety profile in patients with neoplasms.

Published in JAAD International

ISSN: 2666-3287 (Online)
Publisher: Elsevier
Country of publisher: United States
LCC subjects: Medicine: Dermatology
Website: https://www.journals.elsevier.com/jaad-international

About the journal

Abstract

Keywords